P1/2, N=40, Terminated, NextCure, Inc. | Trial completion date: Oct 2024 --> Jan 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2024 --> Jan 2024; Due to the limited activity in Phase 1, NextCure decided to discontinue development of the anti-B7-H4 antibody monotherapy trial (NC762-01) to move forward with a prioritized B7-H4 ADC program.

9 months ago

Trial completion date • Trial termination • Trial primary completion date • Metastases

NC762

12ms

A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)

P1/2, N=40, Active, not recruiting, NextCure, Inc. | Recruiting --> Active, not recruiting | N=170 --> 40

12 months ago

Enrollment closed • Enrollment change • Metastases

NC762